Clinical trial
a Multicenter, Randomized, Double-blind Phase II Trial To Evaluate Monosialate Tetrahexose-ganglioside Sodium Injection (GM1) for Prevention of Peripheral Neuropathy in Patients With Breast Cancer Induced by Albumin-bound Paclitaxel Regimen Adjuvant/Neoadjuvant Therapy
NCT05802342 is registered in ClinicalTrials.gov with Qilu Pharmaceutical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- a Multicenter, Randomized, Double-blind Phase II Trial To Evaluate Monosialate Tetrahexose-ganglioside Sodium Injection (GM1) for Prevention of Peripheral Neuropathy in Patients With Breast Cancer Induced by Albumin-bound Paclitaxel Regimen Adjuvant/Neoadjuvant Therapy
- Lead sponsor
- Qilu Pharmaceutical Co., Ltd.
- Phase
- Phase 2/3
- Overall status
- Unknown status
- Start date
- April 20, 2023
- Completion date
- December 31, 2025
- Enrollment
- 150 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
to evaluate the effectiveness of gm1 in the prevention of albumin-paclitaxel therapy induced peripheral neuropathy in breast cancer patients